BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).

The names of the study drugs involved in this study are/is:

• BXCL701

Study Overview

• Status: Recruiting
• Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
• Intervention / Treatment: Drug: BXCL701

Detailed Description

This is a multi-center, single-arm, Phase I research study for the study drug, BXCL701, for participants with refractory or relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2). Phase I clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means the drug is being studied. BXCL701 is a synthetic dipeptide that is in tablet form and is taken by mouth.

The U.S. Food and Drug Administration (FDA) has not approved BXCL701 as a treatment for any disease.

Research study procedures include screening for eligibility and study treatment including evaluations, blood collections, bone marrow biopsies, and follow up visits.

Participation in this study will last approximately 3 years.

It is expected that about 24 people will participate in this study.

BioXcel is supporting this research study by providing the study drug and funding research tests and procedures.

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Eric S Winer, MD; Phone Number: 1 617-632-2053; Email: erics_winer@dfci.harvard.edu
• Study Contact Backup: Name: Eric S Winter, MD; Phone Number: 1 617-632-2053; Email: erics_winer@dfci.harvard.edu

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Recruiting
      • Dana Farber Cancer Institute
      • Contact: Eric s Winer, MD; Phone Number: 617-632-3000; Email: EricS_Winer@DFCI.HARVARD.EDU
      • Principal Investigator: Eric S. Winer, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 18 and older

• Subjects with evidence of AML that meet at least one of the following criteria:

  • Relapsed AML: as evidence by ≥5% myeloblasts in the bone marrow, or reappearance of blasts in the peripheral blood
  • Refractory AML: ≤2 prior induction regimens (example: patients who receive 7 + 3 followed by 5 + 2 would count as one induction regimen) OR
  • Subjects with WHO defined myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) as defined by blast count between 10% - 19% in the bone marrow or peripheral blood blasts 5% - 19% or Auer rods noted and who are refractory or relapsed after at least 4 cycles of a hypomethylating agent (azacitidine, decitabine, or oral decitabine/cedazuridine)
• ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix B).

• Participants must have adequate organ and marrow function as defined below:

  • Estimated Creatinine Clearance ≥30 mL/min by Cockcroft-Gault calculation
  • Total Bilirubin ≤1.5 x ULN*
  • ALT and AST ≤3x ULN*
  • EF >35%: *unless considered due to leukemic organ involvement. NOTE: Subjects with Gilbert's Syndrome may have a total bilirubin >1.5 x ULN per discussion with overall study PI.
• WBC <25,000 / µL on day of 1 of cycle 1; cytoreduction is permitted with hydroxyurea which is allowed throughout cycle 1 until cycle 2 day 1
• Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
• For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
• Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
• Participants with treated central nervous system (CNS) disease are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression
• Male subjects must agree to refrain from unprotected sex and sperm donation from initial drug administration until 90 days after the last dose of study drug.
• Females of childbearing potential (i.e not postmenopausal for at least 1 year or not surgically sterile) must have negative results by a serum pregnancy test performed within 7 days of day 1. Females must agree to refrain from unprotected sex/adequate contraception via barrier method from initial drug administration until 90 days after the last dose of study drug.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Subjects who have known Acute Promyelocytic Leukemia.
• Subjects with active CNS involvement with AML.
• Participants who have had chemotherapy, other investigational therapy, immunotherapy, or radiotherapy within 2 weeks or 5 half-lives from prior therapy, whichever is longer, prior to the first dose of study medication. Hydroxyurea is allowed with no required washout, and hydroxyurea may be administered for the first cycle of the protocol for patients who have proliferative disease (WBC <25K) with a maximum allowed dose of 6 g per day.
• Participants who have received oral tyrosine kinase inhibitors (TKIs) within two weeks or 5 half-lives (whichever is longer) of the first dose of study medication
• Subjects who are <100 days from allogeneic bone marrow transplant.
• Subjects who have active graft-versus host disease are not eligible. Patients should be off calcineurin inhibitors for at least 28 days (4 weeks) prior to start of study treatment C1D1
• Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities >Grade 1) with the exception of alopecia.
• Participants who are receiving any other investigational agents.
• Concomitant medications: It is strongly encouraged that patients who are on strong inducers or inhibitors of CYP3A4 be changed to a comparable drug if possible. If not possible, then dose reductions will need to be made as per APPENDIX C. Patients are not permitted to be on a gliptin (sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin).
• Patients with a history of orthostatic hypotension with a baseline SBP <100, or history of uncontrolled hypertension.
• Subject has cardiovascular disability status of NYHA class ≥2
• No concurrent active malignancies are allowed on study for ≥2 years prior to treatment start with the exception of currently treated basal cell or squamous cell carcinoma of the skin, carcinoma in-situ of the cervix or breast, or low-grade prostate cancer.
• Patients with known active hepatitis B virus (HBV) infection should be excluded because of potential effects on immune function and/or drug interactions. However, if a patient has HBV history with an undetectable HBV load by polymerase chain reaction (PCR), no liver-related complications, and is on definitive HBV therapy, then he/she would be eligible for study.
• Patients with known active hepatitis C virus (HCV) infection. Patients with a history of HCV infection who received definitive therapy and has an undetectable viral load by PCR would be eligible.
• Participants with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Any other prior or ongoing condition, in the opinion of the investigator, that could adversely affect the safety of the patient or impair the assessment of study results. As patients with AML and MDS are prone to infections, if patients are actively being treated with appropriate antibiotics or antifungal therapy with clinical evidence of infection control, then they will be considered eligible for study.
• Participants with psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women are excluded from this study because BXCL701 has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued.
• Inclusion of Women and Minorities: Both men and women of all races and ethnic groups are eligible for this trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose Escalation BXCL701; Dose escalation will occur using a 3+3 dose escalation approach, evaluating 4 different dose levels of BXCL701. During each 28 day study cycle participants will take BXCL701 2x daily for up to 12 cycles.	Drug: BXCL701; Tablet, taken Orally; Other Names: Talabostat

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Tolerated Dose (MTD)	Defined as the highest dose at which fewer than one-third of patients experience a dose-level toxicity (DLT). MTD will be used to inform recommended Phase II dose. If no DLTs are observed, the MTD is not reached.	From initiation of therapy to day 28, up to 35 days
Number of Participants with treatment related Adverse Events per CTCAE 5.0	Assessed using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	4 weeks up to 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete Remission (CR) Rate	Proportion of patients who have the response, criteria are based upon International Working Group (IWG) and European LeukemiaNet (ELN) criteria for Acute Myeloid Leukemia (APPENDIX D) and Myelodysplastic Syndrome (APPENDIX F).	Disease assesment at baseline, cycle 1, 3 , 8, 15 , 22, and day 1 of every cycle and up to 12 cycles, corresponding to a treatment duration up to one year (each cycle is 28 days).
Complete Response with Incomplete Count Recovery (CRi) Rate	Proportion of patient who has the response, criteria are based upon International Working Group (IWG) and European LeukemiaNet (ELN) criteria for Acute Myeloid Leukemia (APPENDIX D) and Myelodysplastic Syndrome (APPENDIX F).	Disease assesment at baseline, cycle 1, 3 , 8, 15 , 22, and day 1 of every cycle and up to 12 cycles, corresponding to a treatment duration up to one year (each cycle is 28 days).
Partial Response (PR) Rate	Based upon International Working Group (IWG) and European LeukemiaNet (ELN) criteria for AML (APPENDIX D) and MDS (APPENDIX F). Defined as decrease by >= 50% in blast percentage to 5-25% or to <= 5% with auer rods present in marrow; normalization neutrophil count >= 1000μL and platelet count >= 100000μL.	Disease assesment at baseline, cycle 1, 3 , 8, 15 , 22, and day 1 of every cycle and up to 12 cycles, corresponding to a treatment duration up to one year (each cycle is 28 days)..
Morphologic Leukemia-free State (MLFS) Rate	Evaluated only in AML patients per the 2017 ELN criteria (Dohner, Blood 2017, PMID: 27895058), defined as: Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required.	Disease assesment at baseline, cycle 1, 3 , 8, 15 , 22, and day 1 of every cycle and up to 12 cycles, corresponding to a treatment duration up to one year (each cycle is 28 days).
Hematologic Improvement (HI) Rate	Evaluated only in MDS-EB-2 patients.	Disease assesment at baseline, cycle 1, 3 , 8, 15 , 22, and day 1 of every cycle and up to 12 cycles, corresponding to a treatment duration up to one year (each cycle is 28 days).
Median Overall Survival	OS is based on the Kaplan-Meier method, defined as the time from study entry to death or censored at date last known alive.	up to 2 years
Median Duration of Response (DOR)	Defined as the time of first morphologic response until the earlier of progression of disease or death due to any cause.	up to 2 years
Maximum Concentration (Cmax)	Defined as the maximum concentration of BCXL701 over the collection period.	Pharmacokinetic sampling is collected Cycle 1 Day 1, 3, 8, 15, Day 22, and Cycle 2 Day 1 (each cycle is 28 days)

Collaborators and Investigators

• Sponsor: Eric Stephen Winer, MD
• Investigators: Principal Investigator: Eric S Winter, MD, Dana-Farber Cancer Institute

Study record dates

Study Major Dates

• Study Start (Actual): February 2, 2023
• Primary Completion (Estimated): March 17, 2026
• Study Completion (Estimated): July 31, 2026

Study Registration Dates

• First Submitted: November 16, 2022
• First Submitted That Met QC Criteria: January 26, 2023
• First Posted (Actual): January 30, 2023

Study Record Updates

• Last Update Posted (Actual): July 18, 2025
• Last Update Submitted That Met QC Criteria: July 17, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Myelodysplastic Syndrome with Excess Blasts-2
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Neoplasms by Histologic Type; Disease; Hematologic Diseases; Precancerous Conditions; Bone Marrow Diseases; Anemia; Anemia, Refractory; Syndrome; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Myelodysplastic Syndromes; Anemia, Refractory, with Excess of Blasts
• Other Study ID Numbers: 22-379

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
• IPD Sharing Time Frame: Data can be shared no earlier than 1 year following the date of publication
• IPD Sharing Access Criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No